How big is Aadi Bioscience, Inc.?

As of Jun 18, Aadi Bioscience, Inc. has a market capitalization of 94.69 million and net sales of 27.77 million with a net profit of 27.62 million over the latest four quarters. As of Dec 24, shareholder's funds are 52.48 million and total assets are 70.71 million.

As of Jun 18, Aadi Bioscience, Inc. has a market capitalization of 94.69 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 27.77 million, while the sum of net profit for the same period is 27.62 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 52.48 million and total assets of 70.71 million.

What does Aadi Bioscience, Inc. do?

Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing treatments for ocular diseases and diabetic complications. As of March 2025, it reported net sales of $7 million and a net profit of $73 million, with a market cap of $94.69 million.

Overview:<BR>Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing compounds to treat ocular diseases and diabetic complications within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 7 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 73 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 94.69 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 3.00<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.04<BR>- Return on Equity: 13.64%<BR>- Price to Book: 0.43<BR><BR>Contact Details:<BR>- Address: 9987 Carver Rd, BLUE ASH OH: 45242-5550<BR>- Tel: 1 513 9851920<BR>- Website: https://aerpio.com/

Should I buy, sell or hold Aadi Bioscience, Inc.?

Is Aadi Bioscience, Inc. overvalued or undervalued?

As of May 8, 2025, Aadi Bioscience, Inc. is considered an attractive investment due to its undervalued status with a P/E ratio of 3, a Price to Book Value of 0.40, and a high ROCE of 648.45%, despite a year-to-date stock decline of 38.19%, indicating significant growth potential compared to its peers.

As of 8 May 2025, Aadi Bioscience, Inc. has moved from a risky to an attractive valuation grade. The company is currently considered undervalued, with a P/E ratio of 3, a Price to Book Value of 0.40, and an impressive ROCE of 648.45%. In comparison, its peer Theseus Pharmaceuticals, Inc. has a P/E ratio of -3.17, while Vaxart, Inc. is rated risky with a P/E of -2.34, highlighting Aadi's relative strength in valuation metrics.<BR><BR>Despite recent stock performance showing a year-to-date decline of 38.19% compared to a 2.44% gain in the S&P 500, the company's low PEG ratio of 0.02 suggests significant growth potential. Overall, Aadi Bioscience appears to be an attractive investment opportunity within its sector, particularly given its favorable ratios compared to peers.

Is Aadi Bioscience, Inc. technically bullish or bearish?

As of September 11, 2025, Aadi Bioscience, Inc. shows a neutral trend with mixed technical signals, having underperformed the S&P 500 year-to-date but outperformed it over the past month, suggesting a cautious investment approach.

As of 11 September 2025, the technical trend for Aadi Bioscience, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the Bollinger Bands show a mildly bullish weekly signal but a mildly bearish monthly signal. The moving averages indicate a mildly bearish trend on the daily chart, and the Dow Theory shows no trend on the weekly but is mildly bearish on the monthly. <BR><BR>In terms of performance, Aadi Bioscience has underperformed the S&P 500 year-to-date with a return of -37.56% compared to the S&P's 12.22%, but has outperformed over the past month with a return of 22.36% versus the S&P's 2.33%. Overall, the technical indicators suggest a cautious approach given the mixed signals and recent trend change.